Last $244.35 USD
Change Today -0.51 / -0.21%
Volume 717.2K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Open
$244.32
Previous Close
$244.86
Day High
$245.21
Day Low
$243.18
52 Week High
07/18/14 - $258.55
52 Week Low
08/30/13 - $109.96
Market Cap
48.0B
Average Volume 10 Days
800.6K
EPS TTM
--
Shares Outstanding
196.5M
EX-Date
09/3/14
P/E TM
--
Dividend
$0.23
Dividend Yield
0.24%
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc-adr (SHPG) Key Developments

GlaxoSmithKline and Shire Looking To Acquire Tekmira Pharmaceuticals

GlaxoSmithKline plc (LSE: GSK) and Shire plc (LSE:SHP) are rumoured to be eyeing Tekmira Pharmaceuticals Corporation (TSX: TKM) according to Daily Mail. Tekmira Pharmaceuticals is developing an experimental treatment for the deadly ebola virus which has already claimed lives of more than 1,000 people in Africa.

Shire plc and ArmaGen Sign Licensing Agreement for Treatment of Hunter Syndrome

Shire plc and ArmaGen announced worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy, or ERT, for the potential treatment of both the central nervous system, or CNS, and somatic manifestations in patients with Hunter syndrome, or MPS II. Under the terms of the agreement, Shire will obtain worldwide commercialization rights for AGT-182 in exchange for payments of approximately $225 million to ArmaGen, including an initial upfront payment of $15 million in cash and equity, an additional equity investment, R&D funding, development milestones and sales milestones, in addition to royalty payments. As part of the agreement, ArmaGen will be responsible for conducting and completing the Phase I/II study which it expects to initiate before the end of 2014, after which point Shire will be responsible for further clinical development, including phase III trials, and commercialization.

Shire plc Announces Results from Two Phase IV ADHD studies

Shire plc has announced results from two Phase IV efficacy and safety studies of Vyvanse compared with Concerta with a placebo reference arm in adolescents aged 13-17 diagnosed with attention-deficit/hyperactivity disorder, or ADHD. In SPD489-406, the forced-dose titration study, Vyvanse was found to be statistically superior to Concerta on the primary efficacy analysis (p = 0.0013) with mean reductions on the ADHD RS-IV total score of 25.4 and 22.1 points, respectively. In SPD489-405, the dose optimization study, neither Vyvanse nor Concerta was found to be statistically superior to the other on the primary efficacy analysis (p = 0.0717), with a larger mean improvement found for Vyvanse than Concerta (mean reductions on the ADHD-RS-IV total score of 25.6 and 23.5 points, respectively). The primary efficacy endpoint for both studies was defined as the change from baseline in ADHD-RS-IV total score at Week 6 and Week 8, respectively. In both studies, the types of adverse events appear to be generally consistent with the known safety profile for Vyvanse established in studies of adolescents with ADHD. The Phase IV, randomized, double-blind, multicenter, parallel-group, active-controlled, forced-dose titration efficacy and safety study with a placebo reference arm was designed to evaluate the efficacy of Vyvanse compared with Concerta in adolescents (13-17 years of age) with ADHD based on DSM-IV-TR criteria (N=547 treated patients). The primary efficacy outcome was defined as the change from baseline at Week 6 (Visit 6) in the ADHD-RS-IV total score. Patients were randomized to Vyvanse, Concerta, or placebo, respectively, and treated for 6 weeks to evaluate safety and efficacy, followed by a 1-week safety follow-up period. The doses evaluated in this study were Vyvanse 70mg and Concerta 72mg daily. Baseline ADHD-RS-IV total scores were 37.3, 37.0, and 36.1 for Vyvanse, Concerta, and placebo, respectively. At the end of the study [Week 6 (Visit 6)], patients treated with Vyvanse experienced a mean 25.4 point reduction in ADHD-RS-IV total score compared with a 22.1 point reduction for Concerta, and a 17.0 point reduction for placebo. Vyvanse was found to be statistically superior to Concerta (p = 0.0013) on the primary efficacy analysis, with an improvement of 3.4 points compared to Concerta on the ADHD-RS-IV total score. Safety and tolerability evaluations of Vyvanse and Concerta included treatment-emergent adverse events (TEAEs), vital signs, and weight. Exclusion criteria included a known history of cardiovascular disease, clinically significant ECG, blood pressure exceeding the 90th percentile for age, sex and height, current psychiatric diagnosis and a history of substance abuse or dependence. In this study, 1 patient treated with Vyvanse, 1 patient treated with Concerta, and 1 patient treated with placebo experienced serious adverse events (SAEs). Sixteen (16) patients on Vyvanse, 15 patients on Concerta, and 1 patient on placebo had TEAEs that led to study discontinuation. The most commonly reported (>=5% of patients) TEAEs in patients taking Vyvanse included decreased appetite, headache, weight decreased, insomnia, dry mouth, dizziness, irritability, nausea, and upper abdominal pain. The most commonly reported (> =5% of patients) TEAEs in patients taking Concerta included decreased appetite, headache, insomnia, irritability, weight decreased, dizziness, nausea, and nasopharyngitis. There were no deaths in this study. The Phase IV, randomized, double-blind, multicenter, parallel-group, active-controlled, dose-optimization efficacy and safety study with a placebo reference arm was designed to evaluate the efficacy of Vyvanse compared with Concerta in adolescents (13-17 years of age) with ADHD based on DSM-IV-TR criteria (N=459 treated patients). The primary efficacy outcome was defined as the change from baseline at Week 8 (Visit 8) in the Attention- eficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) total score. Patients were randomized to Vyvanse, Concerta, or placebo, respectively, and treated for 8 weeks to evaluate safety and efficacy, followed by a 1-week safety follow-up period. At the end of the dose optimization period, 8.2%, 27.2%, and 52.2% of treated patients were receiving Vyvanse doses of 30, 50, and 70mg, respectively. At the end of the dose optimization period, 5.4%, 18.5%, 22.3%, and 46.2% of treated patients were receiving Concerta doses of 18, 36, 54, and 72mg, respectively. Baseline ADHD-RS-IV total scores were 36.6, 37.8, and 38.2 for Vyvanse, Concerta, and placebo, respectively. At the end of the study [Week 8 (Visit 8)], patients treated with Vyvanse experienced a mean 25.6 point reduction in ADHD-RS-IV total score compared with a 23.5 point reduction for Concerta, and a 13.4 point reduction for placebo.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $244.35 USD -0.51

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SHPG.
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
No financial data is available for SHPG.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.